December 5, 2025

Orthofix Medical Inc. (OFIX) Stock Analysis: A 43% Potential Upside in the Medical Devices Sector

Orthofix Medical Inc. (NASDAQ: OFIX) stands out in the healthcare sector, particularly within the medical devices industry, where it has carved out a niche through its..

Tilray Brands, Inc. (TLRY) Stock Analysis: Unpacking a Potential 147% Upside

Tilray Brands, Inc. (NASDAQ: TLRY) stands out in the healthcare sector as a dynamic player in the specialty and generic drug manufacturing niche. Based in Leamington,..

Relay Therapeutics, Inc. (RLAY): Investor Outlook with a 73.75% Potential Upside

Relay Therapeutics, Inc. (NASDAQ: RLAY) is a clinical-stage biotechnology company based in Cambridge, Massachusetts. Specializing in precision medicines, Relay is transforming drug discovery with a focus..

Myriad Genetics, Inc. (MYGN) Stock Analysis: Evaluating a 16.23% Potential Upside Amidst Challenges

Myriad Genetics, Inc. (NASDAQ: MYGN) operates at the forefront of the healthcare sector as a leading player in diagnostics and research. With a market capitalization of..

Altimmune, Inc. (ALT) Stock Analysis: Biotech Innovator with 236.63% Upside Potential Captures Investor Attention

Altimmune, Inc. (ALT), a prominent player in the biotechnology sector, is capturing the spotlight with a potential upside of 236.63% based on the latest analyst ratings...

Theravance Biopharma, Inc. (TBPH) Stock Analysis: A 42.86% Potential Upside in the Biotech Sector

Investors seeking promising opportunities in the healthcare sector might find Theravance Biopharma, Inc. (NASDAQ: TBPH) an attractive prospect. As a biopharmaceutical company focused on developing and..

Treace Medical Concepts, Inc. (TMCI): Investor Outlook Reveals Nearly 100% Upside Potential

Treace Medical Concepts, Inc. (NASDAQ: TMCI), a prominent player in the medical devices industry, has captured investor attention with its innovative approach to orthopedic solutions, particularly..

Autolus Therapeutics plc (AUTL) Stock Analysis: Exploring a Potential 506% Upside

Autolus Therapeutics plc (NASDAQ: AUTL) is a clinical-stage biopharmaceutical company that has been turning heads on Wall Street due to its promising advancements in T cell..

Avanos Medical, Inc. (AVNS) Growth Potential: An Investor’s Insight into the Healthcare Innovator

Avanos Medical, Inc. (AVNS) stands at the intersection of innovation and healthcare, providing essential medical device solutions across a global market. With a market capitalization of..

Oric Pharmaceuticals, Inc. (ORIC): Analyst Consensus Suggests 74% Upside for This Biotech Innovator

Oric Pharmaceuticals, Inc. (NASDAQ: ORIC), a clinical-stage biopharmaceutical company, is drawing considerable attention from investors with its robust pipeline aimed at overcoming cancer resistance mechanisms. With..

Precigen, Inc. (PGEN) Stock Analysis: Unpacking the 206.6% Revenue Growth and 126.67% Potential Upside

Investors with an eye on the biotechnology sector may find Precigen, Inc. (NASDAQ: PGEN) a compelling prospect. This Germantown, Maryland-based biopharmaceutical company, known for its pioneering..

RxSight, Inc. (RXST) Stock Analysis: Navigating a 21.72% Downside Amidst Healthcare Innovation

RxSight, Inc. (RXST), a pioneering player in the healthcare sector, commands attention with its innovative approach to medical devices, particularly in the realm of cataract surgery...

SIGA Technologies Inc. (SIGA) Stock Analysis: A High ROE and Promising Forward P/E Ratio in the Healthcare Sector

SIGA Technologies Inc. (NASDAQ: SIGA) stands out in the healthcare sector, particularly within the specialty and generic drug manufacturing industry. With a market capitalization of $454.02..

Arbutus Biopharma Corporation (ABUS) Stock Analysis: Uncovering a 28.71% Upside Potential in Biotech

For investors with a keen interest in biotechnology, Arbutus Biopharma Corporation (NASDAQ: ABUS) presents an intriguing opportunity. Operating in the healthcare sector, Arbutus is a clinical-stage..

Cullinan Therapeutics, Inc. (CGEM) Stock Analysis: A Biotech Stock with 155% Upside Potential

Cullinan Therapeutics, Inc. (NASDAQ: CGEM), a promising player in the biotechnology sector, is capturing the attention of investors with its potential for significant upside. The company’s..

Verastem, Inc. (VSTM) Stock Analysis: A Biotech Gem with 50% Upside Potential

Verastem, Inc. (NASDAQ: VSTM) has carved out a niche within the competitive and high-stakes biotechnology sector. Based in Needham, Massachusetts, the company is making strides in..

MBX Biosciences, Inc. (MBX) Stock Analysis: Exploring a Potential 91.96% Upside in the Biotech Sector

MBX Biosciences, Inc. (NASDAQ: MBX), a burgeoning name in the biotechnology sector, is capturing investor attention with its innovative approach to addressing endocrine and metabolic disorders...

iRadimed Corporation (IRMD): Investor Outlook on a Promising Medical Device Innovator with a 5.41% Upside

iRadimed Corporation (NASDAQ: IRMD) is making waves in the healthcare sector, particularly in the medical devices industry, with its innovative MRI-compatible solutions. Headquartered in Winter Springs,..

Abivax SA (ABVX) Stock Report: Navigating a Potential 13% Upside Amidst Clinical Advancements

Abivax SA (ABVX), a French biotechnology company headquartered in Paris, is capturing investor attention with its promising clinical-stage therapeutics designed to stabilize immune responses in patients..

Enliven Therapeutics, Inc. (ELVN) Stock Analysis: Biotechnology Gem with 93% Potential Upside

Enliven Therapeutics, Inc. (NASDAQ: ELVN) is attracting attention in the biotechnology sector with a notable 93.34% potential upside, according to analyst ratings. This Boulder, Colorado-based clinical-stage..

Search

Funds

December 5, 2025

Search

Funds

December 5, 2025

FTSE 100

Funds